Quick Takeaways
- INDP - Indaptus Therapeutics, Inc. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q1 2026.
- Headline metric: Return On Equity -588%.
- Info
- Insider Trading
- Financials
Indaptus Therapeutics, Inc. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2026.
- Symbol
- INDP on Nasdaq
- Location
- New York, NY
- Fiscal year end
- 31 December
- Latest financial report
- 17 Mar 2026
What Changed
- Return On Equity YoY change: <span class="text-green-600">+213%</span>.
- Most recent SEC facts end date: 16 Mar 2026.
Why This Matters
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Official SEC Source
Based on latest 10-Q/10-K
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original FilingLatest SEC snapshot (2026-03-16) highlights Return On Equity -587.6%, Return On Assets -250.5%, and Current Ratio 1.51x.
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
25.5/100
Weak Confidence low
Return On Equity
-588%
Metric score 0.0/100
Return On Assets
-250%
Metric score 0.0/100
Financial Health
- Current Ratio
- 1.51x
Strengths
Current Ratio
Watchpoints
Return On Equity, Return On Assets, and NetIncomeLoss YoY
Key metrics snapshot
Return On Equity
-588%
YoY: +213%
Industry median: -43% (n=671)
Return On Assets
-250%
YoY: +86%
Industry median: -48% (n=669)
Current Ratio
1.51x
YoY: -22%
Industry median: 3.39x (n=667)
NetIncomeLoss YoY
-39%
YoY:
Industry median: -0.54% (n=641)
Profitability
| Metric | Latest value | YoY change |
|---|---|---|
| Return On Equity | -588% | +213% |
| Return On Assets | -250% | +86% |
Financial Health
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 1.51x | -22% |
Growth
| Metric | Latest value | YoY change |
|---|---|---|
| NetIncomeLoss YoY | -39% |
Share Metrics
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 2,242,324 | -84% |
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY